Title :

Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.

Author(s) :

Gauthier, Jordan [Auteur]
Poire, Xavier [Auteur]
Gac, Anne-Claire [Auteur]
Leclerc, Mathieu [Auteur]
Guillaume, Thierry [Auteur]
Chalandon, Yves [Auteur]
Nguyen, Stephanie [Auteur]
Forcade, Edouard [Auteur]
Regny, Caroline [Auteur]
Bay, Jacques-Olivier [Auteur]
Bazarbachi, Ali [Auteur]
Rohrlich, Pierre-Simon [Auteur]
Huynh, Anne [Auteur]
Farhi, Jonathan [Auteur]
Marchand, Tony [Auteur]
Malfuson, Jean-Valere [Auteur]
Pilorge, Sylvain [Auteur]
Labussiere-Wallet, Helene [Auteur]
Renard, Cecile [Auteur]
Fornecker, Luc-Matthieu [Auteur]
Detrait, Marie [Auteur]
Dulery, Remy [Auteur]
Delage, Jeremy [Auteur]
Menard, Anne-Lise [Auteur]
Charbonnier, Amandine [Auteur]
Nelken, Brigitte [Auteur]
Jubert, Charlotte [Auteur]
Suarez, Felipe [Auteur]
Peffault De Latour, Regis [Auteur]
Beguin, Yves [Auteur]
Schoemans, Helene [Auteur]
Blaise, Didier [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]

Journal title :

Bone marrow transplantation

Abbreviated title :

Bone Marrow Transplant.

Publication date :

2018-01-12

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

The question of the best donor type between haploidentical (HAPLO) and matched-related donors (MRD) for patients with advanced HL receiving an allogeneic hematopoietic cell transplantation (allo-HCT) is still debated. ...
Show more >The question of the best donor type between haploidentical (HAPLO) and matched-related donors (MRD) for patients with advanced HL receiving an allogeneic hematopoietic cell transplantation (allo-HCT) is still debated. Given the lack of data comparing these two types of donor in the setting of non-myeloablative (NMA) or reduced-intensity (RIC) allo-HCT, we performed a multicentre retrospective study using graft-vs.-host disease-free relapse-free survival (GRFS) as our primary endpoint. We analysed the data of 151 consecutive HL patients who underwent NMA or RIC allo-HCT from a HAPLO (N = 61) or MRD (N = 90) between January 2011 and January 2016. GRFS was defined as the probability of being alive without evidence of relapse, grade 3-4 acute GVHD or chronic GVHD. In multivariable analysis, MRD donors were independently associated with lower GRFS compared to HAPLO donors (HR = 2.95, P < 0.001). Disease status at transplant other than CR was also associated with lower GRFS in multivariable analysis (HR = 1.74, P = 0.01). In addition, the administration of ATG was independently linked to higher GRFS (HR = 0.52, P = 0.009). In summary, we observed significantly higher GRFS in HL patients receiving an allo-HCT using the HAPLO PT-Cy platform compared to MRD.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Research team(s) :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Submission date :

2019-03-01T14:18:00Z